CIK 0001672619
- Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811523849
- Phone
- +1 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,000 shares at $22.55 ($67,655)
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at an average $20.34 ($135,574)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 7,500 shares at $20.03 ($150,220)
- 4 Planned sale PRESIDENT AND CEO sold 7,500 shares at $20.05 ($150,352)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $16.18 ($52,593)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 5,000 shares at $16.31 ($81,534)
- 4 Planned sale PRESIDENT AND CEO sold 5,000 shares at $16.49 ($82,453)
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at an average $18.39 ($122,579)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 7,500 shares at an average $20.05 ($150,391)
- 4 Planned sale PRESIDENT AND CEO sold 7,500 shares at an average $20.06 ($150,415)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at an average $18.69 ($60,738)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 5,000 shares at an average $16.07 ($80,366)
- 4 Planned sale PRESIDENT AND CEO sold 5,000 shares at $16.42 ($82,096)
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at an average $18.04 ($120,269)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $21.33 ($69,321)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 1,000 shares at $22.50 ($22,505)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at $20.61 ($257,575)
- 4 Planned sale PRESIDENT AND CEO sold 12,500 shares at $20.83 ($260,320)
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at $21.44 ($142,936)
- 4 Exercise or conversion CHIEF FINANCIAL OFFICER acquired 10,000 shares (option exercise)
Page 5 of 20 · 383 filings